HighTower Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

HighTower Advisors’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$466K	Buy	85,838 +1,919	+2%	+$8.06K	﹤0.01%	2802
2026 Q1	$258K	Sell	83,919 -1,932	-2%	-$5.92K	﹤0.01%	3295
2025 Q4	$306K	Buy	85,851 +4,489	+6%	+$16.6K	﹤0.01%	3033
2025 Q3	$284K	Hold	81,362	–	–	﹤0.01%	3089
2025 Q2	$167K	Hold	81,362	–	–	﹤0.01%	3360
2025 Q1	$92.8K	Hold	81,362	–	–	﹤0.01%	3379
2024 Q4	$25.1K	Hold	81,362	–	–	﹤0.01%	3524
2024 Q3	$27K	Buy	81,362 +53,382	+191%	+$22.1K	﹤0.01%	3485
2024 Q2	$13K	Hold	27,980	–	–	﹤0.01%	3427
2024 Q1	$44K	Buy	+27,980	New	+$53.2K	﹤0.01%	3270

Other funds holding STLN

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

KWA

Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

T3 Companies New York $93.7M AUM

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

IAAG

Innovative Asset Advisors Group Shelton, Connecticut $229M AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HighTower Advisors's STLN Position: Q2 2026 in Review

HighTower Advisors increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 2.3% in Q2 2026, buying an estimated $8.06K and bringing the position to 85,838 shares worth $466K. The position accounts for ﹤0.01% of the portfolio, ranked #2802.

HighTower Advisors first reported a position in STLN in Q1 2024 and has held it in 10 quarters since. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

HighTower Advisors held 85,838 shares of Starling Oncology Institute, Inc. Common Stock worth $466K as of Q2 2026.
HighTower Advisors bought 1,919 Starling Oncology Institute, Inc. Common Stock shares in Q2 2026, an estimated $8.06K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2802 holding.
HighTower Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2024 and has held it in 10 quarters since.
29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.